Iterum Therapeutics plc (ITRM) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Dublin, Ireland. The current CEO is Corey N. Fishman.
ITRM has IPO date of 2018-05-25, 9 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $1.6M.
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
